# Becton Dickinson & Co: Form 10-Q for the period ended Mar 31, 2011

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2011-05-04
- Accepted by EDGAR: May 4, 2011, 09:49 ET
- Period: 2011-03-31
- Accession: 0000950123-11-044344
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000095012311044344/y90842e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000095012311044344/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-01-01 to 2011-03-31 | $1.92bn | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2010-10-01 to 2011-03-31 | $3.76bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2011-01-01 to 2011-03-31 | $920.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2010-10-01 to 2011-03-31 | $1.79bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2011-01-01 to 2011-03-31 | $441.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2010-10-01 to 2011-03-31 | $889.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-01-01 to 2011-03-31 | $440.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2010-10-01 to 2011-03-31 | $853.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-01-01 to 2011-03-31 | $23.9m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2010-10-01 to 2011-03-31 | $39.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-01-01 to 2011-03-31 | $117.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2010-10-01 to 2011-03-31 | $211.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-01-01 to 2011-03-31 | $312.0m | us-gaap:ProfitLoss |
| Net income | 6 months, 2010-10-01 to 2011-03-31 | $628.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2011-01-01 to 2011-03-31 | $1.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2010-10-01 to 2011-03-31 | $2.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-01-01 to 2011-03-31 | $1.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2010-10-01 to 2011-03-31 | $2.80 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-01-01 to 2011-03-31 | 225,467,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2010-10-01 to 2011-03-31 | 229,529,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2010-10-01 to 2011-03-31 | $706.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2010-10-01 to 2011-03-31 | $193.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2010-10-01 to 2011-03-31 | $182.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months, 2010-10-01 to 2011-03-31 | $1.06bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2011-03-31 | $748.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-03-31 | $4.86bn | us-gaap:AssetsCurrent |
| Total assets | at 2011-03-31 | $10.34bn | us-gaap:Assets |
| Current liabilities | at 2011-03-31 | $1.58bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2011-03-31 | $241.4m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2011-03-31 | $5.10bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2011-03-31 | 218,751,720 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 38,476 characters.

#### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Our business consists of three worldwide business segments — BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives.

#### Overview of Financial Results

Second quarter revenues of $1.922 billion represented an increase of 6.8% from the same period a year ago, and reflected volume increases of just over 5% and favorable foreign currency translation of 2%, partially offset by price decreases of less than 1%. Second quarter revenue growth reflected an unfavorable comparison to the prior year’s quarter that included strong H1N1 flu pandemic sales, supplemental spending in Japan and U.S. stimulus orders. We estimate that this unfavorable comparison lowered revenue growth for the quarter by approximately 2 percentage points. Sales in the United States of safety-engineered devices in the second quarter of 2011 were $264 million, representing an increase of less than 1% from the prior year’s period. International sales of safety-engineered devices of $178 million in the second quarter of 2011 grew 20% above such sales in the prior year’s period, including an estimated $8 million, or 6%, favorable impact due to foreign currency translation. International safety-engineered device revenue growth continues to be driven by double-digit growth in the Medical segment, with the largest growth in emerging markets, including China and Latin America.

Our financial condition continues to remain strong, with cash flows from continuing operating activities totaling $707 million in the first six months of 2011. In March 2011, we completed the acquisition of Accuri Cytometers, Inc. (“Accuri”), an Ann Arbor, Michigan-based company that develops and manufactures personal flow cytometers for researchers. For further discussion of this acquisition, refer to Note 9 in the Notes to Condensed Consolidated Financial Statements. In November 2010, we issued $700 million of 10-year 3.25% notes and $300 million of 30-year 5.00% notes, as discussed further below. Also, we continued to return value to our shareholders as we repurchased $1.058 billion of our common stock and paid cash dividends of $183 million in the first six months of 2011.

We face currency exposure each reporting period that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. From time to time, we purchase forward contracts and options to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. As of March 31, 2011, we had not entered into contracts to hedge cash flows in fiscal year 2011.

The favorable net impact of foreign currency on revenues for the quarter reflected favorable foreign currency translation and a favorable comparison resulting from hedge losses recognized in the prior year’s period. For further discussion of the hedge losses recognized in the prior year’s period, refer to Note 12 in the Notes to Condensed Consolidated Financial Statements.

The results for the second quarter and six-month period ending March 31, 2011 were unfavorably impacted by the earthquake and tsunami in Japan. However, order volumes for BD products in Japan have now returned to normal levels. Our manufacturing plant in Fukushima sustained some earthquake-related damage, but the prepared plated media manufacturing lines were recently restarted, and manufacturing of BD HypakTM Prefillable Syringes is expected to resume during the third fiscal quarter of 2011. Our Fukushima distribution center and an additional distribution center near Tokyo are in operation. We estimate the unfavorable impact of these natural disasters on our revenues in the second fiscal quarter of 2011 was less than $10 million. For the total fiscal year 2011, we anticipate these events to have an aggregate unfavorable impact of $10 to $20 million on revenues, or about $0.05 diluted earnings per share from continuing operations.

The recently-enacted U.S. healthcare reform legislation contains certain tax provisions that will affect BD. The most significant impact is the medical device excise tax which imposes a 2.3% tax on certain U.S. sales of medical devices, beginning in January 2013. Sales of BD products that we estimate to be subject to this tax represented approximately 80% of BD’s total U.S. revenues in fiscal year 2010. This legislation also included a tax provision that eliminated the employer deduction of the Medicare Part D retiree drug subsidy and, as a result, we recorded a charge of $8.9 million, or $0.04 diluted earnings per share from continuing operations, in the second fiscal quarter of 2010.

#### Results of Operations

#### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

Second quarter revenues of $981 million represented an increase of $60 million, or 6.5%, compared with the prior year’s quarter, including an estimated $15 million, or 2%, favorable impact due to foreign currency translation.

The following is a summary of second quarter revenues by organizational unit:

| (millions of dollars) | Three months ended March 31, 2011 | 2010 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Medical Surgical Systems | $505 | $481 | 4.8% | 2.5% |
| Diabetes Care | 208 | 188 | 10.5% | 2.4% |
| Pharmaceutical Systems | 269 | 252 | 6.6% | (0.7)% |
| Total Revenues\* | $981 | $922 | 6.5% | 1.6% |

\* Amounts may not add due to rounding

Medical revenues reflected strong growth of Diabetes Care revenues, which was primarily attributable to pen needle sales. Segment growth was also aided by strong sales in the Pharmaceutical Systems unit, as well as international safety-engineered product sales. Medical revenue growth reflected an unfavorable comparison to the prior year period that included strong sales related to the H1N1 flu pandemic. We estimate that this unfavorable comparison lowered Medical’s revenue growth by approximately 2 percentage points. Global sales of safety-engineered products were $205 million, as compared with $194 million in the prior year’s quarter, and included an estimated $4 million favorable impact due to foreign currency translation. For the six-month period ended March 31, 2011, global sales of safety-engineered products were $418 million, as compared with $415 million in the prior year’s period, and included an estimated $5 million favorable impact due to foreign currency translation. Total Medical revenues for the six-month period ended March 31, 2011 increased by 1% from the prior-year six-month period, primarily as a result of the favorable impact from foreign currency translation.

Medical operating income for the second quarter was $287 million, or 29.3% of Medical revenues, compared with $263 million, or 28.6% of segment revenues, in the prior year’s quarter. Gross profit margin was higher in the current quarter than the second quarter of 2010 due to increased sales of products with relatively higher gross margins and continued strength in manufacturing productivity, and lower manufacturing start-up costs, as well as net favorable foreign currency translation. These favorable impacts on gross profit margin were partially offset by increases in certain raw material costs and higher pension costs allocated to the segment. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Medical revenues in the second quarter of 2011 was lower than the comparable percent in the second quarter of 2010, primarily due to continued spending controls and favorable foreign currency translation, partially offset by higher pension costs. Research and development expenses for the quarter increased $6 million, or 18% above the prior year’s period, reflecting increased investment in new products and platforms. Segment operating income for the six-month period was $563 million, or 29.5% of Medical revenues, compared with $566 million, or 29.9% in the prior year’s period.

#### Diagnostics Segment

Second quarter revenues of $605 million represented an increase of $50 million, or 9%, over the prior year’s quarter, including an estimated $13 million, or approximately 2%, favorable impact due to foreign currency translation.

The following is a summary of second quarter revenues by organizational unit:

| (millions of dollars) | Three months ended March 31, 2011 | 2010 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $306 | $288 | 6.5% | 2.1% |
| Diagnostic Systems | 299 | 268 | 11.6% | 2.6% |
| Total Revenues | $605 | $556 | 8.9% | 2.4% |

Diagnostics revenue growth reflected solid growth in sales of Preanalytical Systems safety-engineered products. Segment revenue also reflected strong growth in the Diagnostic Systems unit’s infectious disease platforms, primarily MRSA and C-Difficile, as well as growth in sales of TriPath instruments outside the United States. Global sales of safety-engineered products in the Preanalytical Systems unit totaled $237 million, compared with $218 million in the prior year’s quarter, and included an estimated $5 million favorable impact due to foreign currency translation. For the six-month period ended March 31, 2011, global sales of safety-engineered products in the Preanalytical Systems unit were $476 million as compared with $444 million in the prior year’s period, and included an estimated $6 million favorable impact due to foreign currency translation. Total Diagnostics revenues for the six-month period ended March 31, 2011 increased by 5% from the prior-year six-month period, including an estimated 1% favorable impact from foreign currency translation.

Diagnostics operating income for the second quarter was $156 million, or 25.7% of Diagnostics revenues, compared with $144 million, or 25.9% of segment revenues, in the prior year’s quarter. Gross profit margin was slightly lower in the current quarter compared with the prior year’s quarter due to increases in certain raw material costs and higher pension costs, offset in part by increased sales of products with relatively higher gross margins, lower manufacturing start-up costs and net favorable foreign currency translation. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Diagnostics revenues in the second quarter of 2011 was slightly lower than the comparable percent in the second quarter of 2010 due to continued spending controls and favorable foreign currency translation. Research and development expenses in the second quarter of 2011 increased $5 million, or 14% compared with the prior year’s period, reflecting increased investment in new products and platforms. Segment operating income for the six-month period was $317 million, or 26.3% of Diagnostics revenues, compared with $306 million, or 26.6% in the prior year’s period.

#### Biosciences Segment

Second quarter revenues of $335 million represented an increase of $13 million, or 4%, over the prior year’s quarter, including an estimated $12 million, or 4%, favorable impact due to foreign currency translation.

The following is a summary of second quarter revenues by organizational unit:

| (millions of dollars) | Three months ended March 31, 2011 | 2010 | Total Change | Estimated Foreign Exchange Impact |
| --- | ---: | ---: | ---: | ---: |
| Cell Analysis | $256 | $242 | 5.4% | 3.7% |
| Discovery Labware | 80 | 80 | 0.2% | 3.5% |
| Total Revenues \* | $335 | $322 | 4.1% | 3.7% |

\* Amounts may not add due to rounding

Biosciences’ revenue growth reflected an unfavorable comparison to the prior year’s period that included strong sales from U.S. stimulus spending and supplemental spending in Japan. We estimate that this unfavorable comparison lowered Biosciences’ revenue growth by approximately 8 percentage points. We also estimate that the recent earthquake and tsunami that occurred in Japan also unfavorably impacted revenue growth by approximately 3 percentage points. Revenue growth of the segment was primarily driven by instrument and reagent sales in the Cell Analysis unit. For the six-month period ended March 31, 2011, total Biosciences revenues increased by 4% from the prior-year six-month period, including an estimated 2% favorable impact from foreign currency translation.

Biosciences operating income for the second quarter was $95 million, or 28.4% of Biosciences revenues, compared with $97 million, or 30.2% of segment revenues, in the prior year’s quarter. Gross profit margin, as a percent of Biosciences revenue, was slightly lower in the current quarter than the second quarter of 2010 primarily due to increases in certain raw material costs, higher pension costs allocated to the segment and unfavorable sales mix in the Discovery Labware business. Gross profit margin in the current quarter was also unfavorably impacted by the effects of the earthquake and tsunami in Japan. These unfavorable variances from the prior year’s period were partially offset by increased sales of products and services with relatively higher gross margins, favorable manufacturing costs and net favorable foreign currency translation. See further discussion on gross profit margin below. Selling and administrative expense as a percent of Biosciences revenues for the quarter increased compared with the prior year’s quarter, reflecting Accuri acquisition costs, partially offset by continued spending controls and favorable foreign currency translation. Research and development spending in the quarter increased $5 million, or 20% above the prior-year period, reflecting increased investment in new products and platforms. Segment operating income for the six-month period was $186 million, or 28.6% of Biosciences revenues, compared with $183 million, or 29.2% in the prior year’s period.

#### Geographic Revenues

Revenues in the United States for the second quarter of $829 million represented an increase of $37 million, or 5%, over the prior year’s quarter. U.S. Medical revenues reflected strong sales of pen needles and Pharmaceutical Systems products, offset by weaker sales in the Medical Surgical Systems unit. U.S. Diagnostics revenue growth was driven by increased infectious disease testing. Biosciences revenue growth in the United States reflected an unfavorable comparison to the prior year’s period which included U.S. stimulus spending. Revenue growth in Biosciences was driven by the Cell Analysis unit, partially offset by weaker sales of Discovery Labware products.

International revenues for the second quarter of $1.093 billion represented an increase of $85 million, or 8.5%, over the prior year’s quarter, including an estimated $39 million, or 4%, favorable impact due to foreign currency translation. International revenue growth was unfavorably impacted by an estimated 2 percentage points due to an unfavorable comparison to the prior year, which included strong sales related to the H1N1 flu pandemic and supplemental spending in Japan. We experienced solid growth in both the Medical and Diagnostics segments. Biosciences revenue growth was 5% for the quarter and included an estimated 6% favorable impact due to foreign currency translation. International revenue growth in the Biosciences segment reflected an unfavorable impact of an estimated 16 percentage points resulting from both the unfavorable comparison to the prior year’s period which included supplemental spending in Japan, and the impact of the natural disasters in Japan.

#### Gross Profit Margin

Gross profit margin was 52.1% for the second quarter, compared with 52.0% for the comparable prior-year period. Gross profit margin in the second quarter of 2011 as compared with the prior year’s period reflected an estimated net favorable impact of 40 basis points relating to foreign currency translation. The operating performance impact on gross margin was unfavorable by 10 basis points as compared with the prior year. This resulted from increases in certain raw material costs and higher pension costs, which were partially offset by increased sales of products with relatively higher gross margins and increased productivity as well as lower manufacturing start-up costs. Gross profit margin was also unfavorably impacted by 20 basis points as a result of the natural disasters in Japan. Gross profit margin in the six-month period of 2011 of 52.6% compared with the prior year’s period of 52.1% reflected an estimated favorable impact of foreign currency translation of 60 basis points. The operating performance impact on gross profit margin in the six-month period of 2011 was flat as increased sales of products with relatively higher gross margins and increased productivity were offset by increases in certain raw material costs and higher pension costs. Gross profit margin in the six-month period of 2011 was also unfavorably impacted by 10 basis points as a result of the natural disasters in Japan.

#### Selling and Administrative Expense

Selling and administrative expense was 23.0% of revenues for the second quarter and 23.6% for the six-month period, compared with 23.4% and 23.6%, respectively, for the prior year’s periods. Aggregate expenses for the second quarter reflected an unfavorable foreign exchange impact of $4 million, an increase in core spending of $10 million, increased pension costs of $4 million, and a $1 million increase in the deferred compensation liability. Aggregate expenses for the quarter also included $2 million related to our global enterprise resource planning initiative to update our business information systems. Aggregate expenses for the six-month period of 2011 reflected $1 million of unfavorable foreign exchange, increases in core spending of $7 million, increased pension costs of $8 million and a $4 million increase in the deferred compensation plan liability, as further discussed below. Aggregate expenses for the six-month period also included $3 million related to our global enterprise resource planning initiative to update our business information systems.

#### Research and Development Expense

Research and development expense was $119 million, or 6.2% of revenues, for the second quarter, an increase of 19% compared with the prior year’s amount of $100 million, or 5.6% of revenues. Research and development expense was $235 million, or 6.2% of revenues, for the six-month period in the current year, compared with the prior year’s amount of $199 million, or 5.4% of revenues. The increases in research and development expenditures for the three-month and six-month periods ending March 31, 2011 compared with the prior year’s periods reflected increased spending for new products and platforms in each of our segments.

#### Non-Operating Expense and Income

Interest income was $15 million in the second quarter compared with $10 million in the prior year’s period. Interest income was $30 million in the six-month period, compared with $18 million in the prior year’s period. The increase in both the three-month and six-month periods ending March 31, 2011 compared with the prior year’s periods resulted from higher interest rates and levels of investments outside the United States, as well as investment gains on assets related to our deferred compensation plan. The related increase in the deferred compensation plan liability was recorded as an increase in selling and administrative expenses. Interest expense was $24 million in the second quarter and $39 million in the six-month period, compared with $13 million and $26 million, respectively, in the prior year’s periods. The increase in both the three-month and six-month periods ending March 31, 2011 compared with the prior year’s periods reflects higher levels of long-term fixed rate debt, partially offset by lower average interest rates on this debt.

#### Income Taxes

The income tax rate was 27.4% for the second quarter, compared with the prior year’s rate of 30.6%. The six-month tax rate was 25.3% compared with the prior year’s rate of 29.3%. The income tax rates for the three-month and six-month periods ending March 31, 2010 reflected a non-cash charge in the prior year’s period related to healthcare reform impacting Medicare Part D reimbursements as discussed earlier in “Overview of Financial Results.” The decrease in the income tax rate in the first six months of 2011 compared with the prior year period’s rate also reflected a favorable impact due to the timing of certain tax benefits. These benefits resulted from the retroactive extension of the U.S. research tax credit as well as a European restructuring transaction, both of which occurred in the first quarter of 2011.

#### Income from Continuing Operations and Diluted Earnings Per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations for the second quarter of 2011 were $311 million and $1.38, respectively. Income from continuing operations and diluted earnings per share from continuing operations for the prior year’s second quarter were $285 million and $1.18, respectively. The current quarter’s earnings reflected an estimated $0.07 favorable impact due to foreign currency translation. The prior year’s second quarter earnings included a $0.04 non-cash charge related to healthcare reform, as previously discussed. For the six-month periods, income from continuing operations and diluted earnings per share from continuing operations were $625 million and $2.72, respectively, in 2011 and $589 million and $2.43, respectively, in 2010. The current period’s earnings reflected an estimated $0.12 favorable impact due to foreign currency translation. The prior-year six-month period’s earnings also included the $0.04 non-cash charge related to healthcare reform.

#### Liquidity and Capital Resources

Cash generated from operations, along with available cash and cash equivalents, including proceeds from the first quarter debt issuance as further discussed below, is expected to be sufficient to fund our normal operating needs. Normal operating needs in fiscal year 2011 include capital expenditures, cash dividends and common stock repurchases. Net cash provided by continuing operating activities was $707 million during the first six months of 2011, compared with $648 million in the same period in 2010. The current period change in operating assets and liabilities was a net use of cash and reflected higher levels of inventory and prepaid expenses, as well as lower levels of trade payables, partially offset by improved collections of accounts receivable. Net cash provided by continuing operating activities in the first six months of 2010 was reduced by changes in the pension obligation resulting partially from discretionary cash contributions of approximately $175 million.

Net cash used for continuing investing activities for the first six months of the current year was $1.024 billion, compared with $471 million in the prior-year period. Cash used for purchases of investments in the current period reflected the extension of maturities of certain highly liquid investments beyond three months. Capital expenditures were $194 million in the first six months of 2011 and $228 million in the same period in 2010. Acquisitions of businesses in the current period reflected the payment of $205 million, net of cash acquired relating to the Accuri acquisition. The prior-year amount reflected the payment of $275 million, net of cash acquired relating to the HandyLab acquisition.

Net cash used for continuing financing activities for the first six months of the current year was $155 million, compared with $778 million in the prior-year period. The prior period’s change in short-term debt reflected the repayment of $200 million of 7.15% Notes, due October 1, 2009. For the first six months of the current year, we repurchased approximately 13.1 million shares of our common stock for $1.058 billion, compared with approximately 5.9 million shares of our common stock for $450 million in the prior-year period. Aggregate common stock repurchases are estimated to be approximately $1.5 billion for the full fiscal year 2011. At March 31, 2011, Board authorization to repurchase an additional 15.5 million common shares remained.

As of March 31, 2011, total debt of $2.7 billion represented 34.3% of total capital (shareholders’ equity, net non-current deferred income tax liabilities, and debt), versus 23.7% at September 30, 2010. Short-term debt decreased to 8.9% of total debt at the end of March 31, 2011, from 12% at September 30, 2010. On November 8, 2010, we issued $700 million of 10-year 3.25% notes and $300 million of 30-year 5.00% notes. The net proceeds from these issuances have been and are expected to be used for general corporate purposes, which may include funding for working capital, capital expenditures, repurchases of our common stock and acquisitions.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $200 million at March 31, 2011. We have available a $1 billion syndicated credit facility with an expiration date in December 2012. This credit facility, under which there were no borrowings outstanding at March 31, 2011, provides backup support for our commercial paper program and can also be used for other general corporate purposes. This credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio has ranged from 23-to-1 to 32-to-1. In addition, we have informal lines of credit outside the United States.

#### Government Receivables

Accounts receivable balances include sales to government-owned or government-supported healthcare facilities. Because these customers are government-owned or supported, we could be impacted by declines in sovereign credit ratings or by defaults in these countries.

In particular, we have experienced significant payment delays in Greece due to the government’s liquidity issues that have affected its ability to process payments to suppliers within Greece’s national healthcare system. During the second quarter of fiscal year 2011, BD received a settlement established by Greece’s government to repay all debts associated with its central government hospitals’ suppliers incurred since 2005. Under the plan, suppliers received cash for debts incurred from 2005 through 2006 and zero-coupon bonds for debts incurred from 2007 through 2009. BD sold the bonds received from the settlement during the second quarter of fiscal year 2011.

We continually evaluate all government receivables, particularly in Spain, Italy, and other parts of Western Europe, for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to government receivables are adequate and this concentration of credit risk is not expected to have a material adverse impact on our financial position or liquidity.

#### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results — are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item IA. Risk Factors in our 2010 Annual Report on Form 10-K and Item 1A. Risk Factors of this report.

- The current conditions in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services, or our ability to produce our products, including the impact on developing countries. Also, the increase in sovereign debt during the financial crisis as a result of governmental intervention in the world economy poses additional risks to the global financial system and economic recovery. We sell to government-owned or government-supported healthcare and research facilities, and any governmental austerity programs or other adverse change in the availability of government funding in these countries, particularly in Western Europe, could result in less demand for our products and additional pricing pressures, as well as create potential collection risks associated with such sales.
- The consequences of the recently-enacted healthcare reform legislation in the United States, which implemented an excise tax on U.S. sales of certain medical devices, and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect BD’s business.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment (including changes in reimbursement practices by third party payors).
- Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, price controls, licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.

33

- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, including increased enforcement activity by the FDA.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The effects of natural disasters, including pandemics, earthquakes, fire, wind or other destructive events, or the effects of climate change, on our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers that are needed for such manufacturing.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain sub-assemblies and finished goods, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product.
- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- Fluctuations in U.S. and international governmental funding and policies for life sciences research.
- Our ability to achieve our projected level or mix of product sales. Our earnings forecasts are based on projected volumes and sales of many product types, some of which are more profitable than others.
- Our ability to implement our ongoing upgrade of our enterprise resource planning system, as any delays or deficiencies in the design and implementation of our upgrade could adversely affect our business.

34

- Pending and potential future litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, patent infringement claims, and the availability or collectibility of insurance relating to any such claims.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers.
- The effect of market fluctuations on the value of assets in BD’s pension plans and to actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government, particularly in light of the recent civil unrest in parts of the Middle East.
- Our ability to penetrate developing and emerging markets, which also depends on economic and political conditions and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology.
- The effects, if any, of future healthcare reform in the countries in which we do business, including changes in government pricing and reimbursement policies or other cost containment reforms.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,021 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of March 31, 2011. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2011 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 919 characters.

**The recent earthquake and tsunami in Japan, and the resulting damage to the Fukushima nuclear power plant, may continue to affect our business operations and financial results.**

Our business in Japan accounts for approximately 5 percent of our total revenues and we source certain component parts and finished products from third-party suppliers in Japan. We also have a manufacturing facility and distribution center within approximately 60 kilometers of the Fukushima nuclear power plant. While our organization and facilities in Japan were not materially damaged by the earthquake and tsunami and our operations there are stabilizing, it is difficult to assess the longer term risks the situation in Japan poses to our business, and there can be no assurance that our financial results will not be adversely affected, particularly in light of standard insurance coverage exclusions related to nuclear incidences.

Filed May 4, 2011.
Source: SEC EDGAR, the filing index for accession 0000950123-11-044344. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
